The paper shows how patient-focused methodologies, enabling technologies and emerging biopharma ecosystems will deliver a step change in the number of treatments needed for the estimated 400 million people living with a rare condition.
Download the white paper below to explore these topics and access exclusive insights from our interviewed experts: Elin Haf Davies (Aparito), Dr Jamie Duckers (Rare Disease Wales), Dave Latshaw (BioPhy), Vaughan Gething (Wales' Economy Minister), Gareth Healey (Life Sciences Hub Wales), and Andrea Tithecott and Christina Sochacki (Al Tamim & Company).
With thanks to the authors, Jordan Taylor and Julie Walters.
For more information, please contact:
Georgia Wilson, Chief of Staff.
Email: georgia.wilson@ambrosehc.com